With One Foot Firmly Planted In Oncology, Roche Moves The Other Into CV/Metabolic

The Swiss drug maker, long a leader in oncology, is vying to become a frontrunner in treating cardiovascular disease and metabolic disorders.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet